Marshall Wace, LLP Petros Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.68 - $1.49 $89,213 - $195,482	-131,196 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.07 - $3.36 $120,785 - $379,290	-112,884 Reduced 46.25%	131,196 $205,000
Q4 2021 Feb 14, 2022	BUY	$1.33 - $4.09 $324,626 - $998,287	244,080 New	244,080 $813,000

Ticker PTPI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 20,708,000
Market Cap $7.04M
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.